Salarius Pharmaceuticals (SLRX) Stock Price, News & Analysis

Company Overview

Salarius Pharmaceuticals, Inc. is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that target epigenetic and post‐translational modification pathways in cancer. The company’s lead candidate, seclidemstat (SP‐2577), is designed to inhibit lysine‐specific demethylase 1 (LSD1) and modulate the tumor microenvironment, with a primary focus on treating Ewing sarcoma, a rare and aggressive bone and soft tissue cancer affecting children and young adults. Seclidemstat is currently being evaluated in Phase 2 clinical studies, where the company is investigating its efficacy and safety profile in patients with relapsed or refractory disease.

In addition to its lead program, Salarius maintains a robust preclinical pipeline of small‐molecule candidates targeting fusion‐driven cancers and other oncology indications. These programs leverage proprietary chemistry platforms to identify novel inhibitors of NEDD8‐activating enzymes and other epigenetic regulators. By addressing oncogenic fusion proteins and key regulatory enzymes that drive tumor growth, Salarius aims to expand its portfolio of precision therapies for patients with unmet medical needs.

Founded in 2014 and headquartered in Houston, Texas, Salarius Pharmaceuticals has assembled a management team with extensive experience in oncology drug development, regulatory strategy, and commercialization. The company’s clinical trials are conducted primarily in the United States, with plans to extend development activities into Europe and other regions as part of its global strategy. Salarius also collaborates with academic institutions, patient advocacy groups and research consortia to advance its programs and accelerate the delivery of new cancer therapies to the clinic.

Key Stats

• Today's Range: $4.16 to $4.55
• 50-Day Range: $3.67 to $8.54
• 52-Week Range: $3.64 to $108.00
• Volume: 195,502 shs
• Average Volume: 179,467 shs
• Market Capitalization: $2.23 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Salarius Pharmaceuticals Stock Analysis - MarketRank™

Salarius Pharmaceuticals scored higher than 17% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Salarius Pharmaceuticals.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Salarius Pharmaceuticals is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Salarius Pharmaceuticals is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Salarius Pharmaceuticals has a P/B Ratio of 0.30. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

10.65% of the float of Salarius Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Salarius Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Salarius Pharmaceuticals has recently decreased by 56.22%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Salarius Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Salarius Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

10.65% of the float of Salarius Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Salarius Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Salarius Pharmaceuticals has recently decreased by 56.22%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.97

News Sentiment

Salarius Pharmaceuticals has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Salarius Pharmaceuticals this week, compared to 1 article on an average week.

Search Interest

1 people have searched for SLRX on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Salarius Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.20% of the stock of Salarius Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Only 11.88% of the stock of Salarius Pharmaceuticals is held by institutions.

SLRX Stock Analysis - Frequently Asked Questions

How have SLRX shares performed this year?

Salarius Pharmaceuticals' stock was trading at $27.60 on January 1st, 2025. Since then, SLRX shares have decreased by 84.3% and is now trading at $4.3450.

How were Salarius Pharmaceuticals' earnings last quarter?

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) issued its quarterly earnings results on Tuesday, August, 12th. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($33.00) by $32.55.

When did Salarius Pharmaceuticals' stock split?

Shares of Salarius Pharmaceuticals reverse split before market open on Tuesday, August 19th 2025.The 1-15 reverse split was announced on Tuesday, August 19th 2025. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, August 19th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Salarius Pharmaceuticals?

Shares of SLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Salarius Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Salarius Pharmaceuticals investors own include Bionano Genomics (BNGO), Tonix Pharmaceuticals (TNXP), Acasti Pharma (ACST), Meta Platforms (META), T2 Biosystems (TTOO), NIO (NIO) and VBI Vaccines (VBIV).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 10/15/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SLRX
• Previous Symbol: NASDAQ:FLKS
• CIK: 1615219
• Web: www.salariuspharma.com
• Phone: (832) 834-6992
• Fax: N/A
• Employees: 20
• Year Founded: 2011

Profitability

• EPS (Trailing Twelve Months): ($43.48)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$5.58 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -556.47%
• Return on Assets: -192.35%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.61
• Quick Ratio: 0.61

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $14.31 per share
• Price / Book: 0.29

Miscellaneous

• Outstanding Shares: 510,000
• Free Float: 504,000
• Market Cap: $2.13 million
• Optionable: Not Optionable
• Beta: 0.44